Paclitaxel adverse reactions (1) allergic reactions. Rate was 39%, of which 2% incidence of severe allergic reactions. Domestic reporting allergic reactions to the 11% -20% rate, the majority of type I allergy, manifested as bronchial recover from illness twin dyspnea, urticaria, chest pain, angioedema and hypotension. Almost all of the reactions have occurred in the first 10min after treatment, the severe reactions often occur after the use of paclitaxel 2-3min.
Paclitaxel adverse events (2) bone marrow suppression. As the main dose-limiting toxicity, manifested as neutropenia, thrombocytopenia is less common, usually 8-10 days after treatment occurred ,15-21 resume. With the recommended dose in serious neutropenia 0.5X109 a / L found in 47% of the patients, duration generally less than 5 days. The incidence of fever throughout the course of about 19%, only 5% of patients a platelet count less than 50X109 / L, anemia (Hb <110g / L) were seen in 90% of patients. It should be noted that the application of G-CSF can reduce the incidence of bone marrow suppression.
(3) neurotoxicity. Peripheral neuropathy found in 62% of all cases, the most common surgery showed mild anesthesia and paresthesia, severe neurologic symptoms occur in approximately 4%, showing that sensory and motor impairment and chest to reduce reflections, occasional weakness. In addition, dark spots can still happen to flash the optic nerve disorder characterized. Paclitaxel doses greater than 170mg/ml, the treatment will occur in future moment myalgia 2-5; doses greater than 250mg/ml, and compatibility with the DDP when more than a myopathy.
(4) cardiovascular toxicity. May have short-term hypotension and asymptomatic bradycardia, which is an incidence of about 29%. ECG abnormalities seen in 30% of the cases, is still visible severe conduction block.
(5) joint pain and muscle pain. Found in 55% of the cases involving the arm and leg joints, the symptoms are mild, often appear in 2-3 days after treatment, the number of days of recovery. Into the incidence and severity was dose dependent, and in patients receiving G-CSF is more common.
Paclitaxel adverse reaction (6), gastrointestinal reactions. Nausea and vomiting, diarrhea and mucositis rates were 59%, 43% and 39%. Generally mild to moderate.
(7) liver toxicity. Expressed as bilirubin, AKP, AST and ALT increased with paclitaxel dose related. There is no data to show that the drug can cause serious liver damage.
(8) hair loss. Can be found in more than 80% of cases, and with the accumulation of treatment, often have full body hair loss.
Paclitaxel adverse reactions (9), intravenous infusion of drugs and drug leakage around the local, occasional local inflammatory reaction, cellulitis, previous radiation field may have inflammatory skin reaction.